Association Of Survivin With Clinical Efficacy And Platinum Drug Resistence In Nsclc

Objective: To investigate the expression of Survivin and its relationshipwith clinical pathological features and curative effect of Platinum chemotherapyregimens in non-small cell lung cancer (NSCLC).Method: This research adopted retrospective analysis to study82patientswith advanced NSCLC who had their first treatment in The Third AffiliattedHospital of Guangxi Medical University university from2006to2011.Immunohistochemical SP method was used to detect the expression overallsurvival on of Survivin protein. Combining the follow-up data and clinicalpathological parameters collected, we analyzed the expression of Survivin in thepathological tissue and its relationship with clinical indicators (gender, age,smoking history, degree of differentiation, clinical stage, histological type), alsowith the response rate, the progression-free survival and the overall survivalafter using platinum-based chemotherapy. SPSS16.0statistical software wasused to analyze the results: chi-square test was used to compare the rate of count date; life-table was used to analyze the1year survival rate; kaplan–Meier wasused to analyze the survival analysis, P <0.05indicated the difference wasstatistically significant.Result: This study found that the expression of Survivin was not relatedto gender, age, pathological type and clinical stage in the82cases of patientswith NSCLC tissues (P>0.05); In the82cases of NSCLC patients,17caseshave negative expression of Survivin in carcinoma tissue pathologic specimens.The chemotherapy objective effective rate of the negative group was30.8%, themedian survival time was11.3months.65cases have positive expression ofSurvivin in carcinoma tissue pathologic specimens. The Objective clinicalefficacy rate was47.1%, the median survival time was9.6months. The twogroups had no significantly statistical differences (χ2=1.590, P=0.255), but theobjective effective rate and the median survival time of the patients with positiveexpression of Survivin was slightly lower than that of the negative group. Whichindicated the positive expression of Survivin may be associated withchemotherapy effect and platinum resistance. In addition, the1-year survivalrate of the patients with positive expression of Survivin was significantly (23.1%)lower than that of the negative group (52.9%). The difference between the twogroups was statistically significant (P=0.033).Conclusion:1. We did not find any significant difference of gender, age,histological type and clinical staging between the positive expression and thenegative expression of Survivin in non-small cell lung cancer tissues.2．In this study we found that the chemotherapy effectiveness and the mediansurvival time of the positive expression group were slightly lower than that ofthe negative group. The1-year survival rate of the patients with positiveexpression of Survivin was23.1%, and the negative group was52.9%. In a word, patients with negative expression of Survivin may get more Survival benefit insome extent. Survivin may become a molecular predictor of individualizedtreatment in NSCLC, it may also have a certain guiding significance in theclinical choice of platinum-based chemotherapy.